Ophthalmic Drug Delivery

Research in ophthalmic drug delivery has developed significant advances in the last few years, and efforts have been made to develop more effective topical formulations to increase drug bioavailability, efficiency, and safety. Drug delivery to the posterior segment of the eye remains a great challen...

Full description

Saved in:
Bibliographic Details
Other Authors: Otero-Espinar, Francisco Javier (Editor), Ferreiro, Anxo Fernández (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_128629
005 20231130
003 oapen
006 m o d
007 cr|mn|---annan
008 20231130s2023 xx |||||o ||| 0|eng d
020 |a books978-3-0365-8796-7 
020 |a 9783036587974 
020 |a 9783036587967 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-8796-7  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
072 7 |a KNDP  |2 bicssc 
100 1 |a Otero-Espinar, Francisco Javier  |4 edt 
700 1 |a Ferreiro, Anxo Fernández  |4 edt 
700 1 |a Otero-Espinar, Francisco Javier  |4 oth 
700 1 |a Ferreiro, Anxo Fernández  |4 oth 
245 1 0 |a Ophthalmic Drug Delivery 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2023 
300 |a 1 electronic resource (330 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Research in ophthalmic drug delivery has developed significant advances in the last few years, and efforts have been made to develop more effective topical formulations to increase drug bioavailability, efficiency, and safety. Drug delivery to the posterior segment of the eye remains a great challenge in the pharmaceutical industry due to the complexity and particularity of the eye's anatomy and physiology. Some advances have been made with the purpose of maintaining constant drug levels in the site of action. The anatomical ocular barriers have a great impact on drug pharmacokinetics and, subsequently, on the pharmacological effect.Despite the increasing interest in efficiently reaching the posterior segment of the eye with reduced adverse effects, there is still a need to expand the knowledge of ocular pharmacokinetics that allow the development of safer and more innovative drug delivery systems. These novel approaches may greatly improve the lives of patients with ocular pathologies. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
650 7 |a Pharmaceutical industries  |2 bicssc 
653 |a excitotoxicity 
653 |a neurodegeneration 
653 |a retina 
653 |a microparticles 
653 |a controlled drug release 
653 |a rebamipide 
653 |a sustained delivery system 
653 |a dry eye 
653 |a eyelid 
653 |a mucin 
653 |a ocular pharmacokinetics 
653 |a ocular drug delivery systems 
653 |a ocular routes of drug administration 
653 |a intravitreal administration 
653 |a topical administration 
653 |a anti-angiogenesis 
653 |a corneal neovascularization (NV) 
653 |a epigallocatechin gallate (EGCG) 
653 |a gelatin 
653 |a hyaluronic acid (HA), nanoparticles 
653 |a RGD peptide 
653 |a eye drops 
653 |a retinal penetration 
653 |a neuroprotection 
653 |a protein aggregation 
653 |a stability 
653 |a intravitreal delivery 
653 |a CNTF 
653 |a corticosteroids 
653 |a drug delivery systems 
653 |a intravitreal dexamethasone implant 
653 |a intravitreal injections 
653 |a Ozurdex 
653 |a drug delivery 
653 |a glaucoma 
653 |a ROCK inhibitor 
653 |a fasudil 
653 |a PLGA microspheres 
653 |a intravitreal injection 
653 |a trabecular meshwork 
653 |a Schlemm's canal 
653 |a retinal pigment epithelium 
653 |a Electric Cell-Substrate Impedance Sensing 
653 |a dexamethasone acetate 
653 |a cyclodextrins 
653 |a hydrogels 
653 |a rheology 
653 |a cytotoxicity studies 
653 |a transcorneal permeation 
653 |a radiolabeled ocular biopermanence 
653 |a blood-retinal barrier 
653 |a cationic drug 
653 |a transport 
653 |a lysosomal trapping 
653 |a atropine 
653 |a ophthalmic solution 
653 |a myopia 
653 |a amphotericin B 
653 |a γ-cyclodextrins 
653 |a fungal keratitis 
653 |a lutein 
653 |a PLGA 
653 |a PLGA-PEG-biotin 
653 |a ARPE-19 
653 |a macular edema 
653 |a age-related macular degeneration 
653 |a biotin-decorated nanoparticles 
653 |a polymeric nanoparticles 
653 |a targeted therapy 
653 |a ocular drug delivery 
653 |a half-life extension 
653 |a albumin 
653 |a therapeutic proteins 
653 |a size exclusion chromatography 
653 |a iron 
653 |a retinal degeneration 
653 |a retinitis pigmentosa 
653 |a transferrin 
653 |a gene therapy 
653 |a plasmid electrotransfection 
653 |a dexamethasone 
653 |a poly(lactic-co-glycolic) acid 
653 |a ophthalmology 
653 |a microspheres 
653 |a periocular administration 
653 |a gamma sterilization 
653 |a tolerance 
653 |a in vitro model 
653 |a in vitro drug release 
653 |a intravitreal implants 
653 |a SLA 3D-printing 
653 |a triamcinolone acetonide 
653 |a USP apparatus 4 
653 |a USP apparatus 7 
653 |a vitreous substitute 
653 |a dissolution 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/8081  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/128629  |7 0  |z DOAB: description of the publication